BioCryst Pharmaceuticals (NASDAQ: BCRX, Stock Forum) is focusing on gout and on cancer these days.
The conference call’s highlights from the Q2 report are here: Please see presentation. BioCryst has good things to say about its clinical testing for a leukemia candidate, for the uric-acid (gout) drug and for its peramivir compound for influenza.
There were a LOT of questions. “Yes, a lot of questions,” business development executive Robert Bennett told me from company headquarters in the southern USA.
This thing is a buy here, especially five weeks ahead of an Investor Day that might explain future molecular compounds in testing for auto-immunes, cancers, viruses out there in the Raleigh-Durham research triangle of the Carolinas.
The company has cash. Some $80 million. Enough to get through another couple years of drug development. What can I say? Jon Stonehouse, the BioCryst CEO, clearly is more of a drug salesman than a molecular compound developer. His lab team is in place, led by Dr. William Sheridan. When BioCryst has more approved drugs to sell, Mr. Stonehouse will be in his element. Or his compound.
There was a lot of interest on the conference call about the gout and leukemia compounds. Merrill Lynch, Oppenheimer, JMP, R&R and MANY others were asking questions about trial methodologies, dosings, efficacies, synergies and coming events for the two drugs in human trials. I suggest listening to the conference call at the above link and at www.BioCryst.com.
There were a lot of questions. You have to like that.
Unless anything changes, I will be adding to our stake of 80,000 shares here at home. That is, if the $6 stock keeps getting hammered as it has with the disappearance of H1N1 influenza from headlines and airport bulletin boards. Peramivir, we learned, or better, I concluded after a slew of Wall Street questions at the end of the call, this influenza compound is still a world-class antiviral with international appeal. This does not go away.
Tim Hart, a Ticker Trax subscriber, says, “I’m not understanding the selloff … and I am placing ‘stink bids’ to take advantage.” Tim, this is exactly what I have done. In my case, except for at the ultra-cheap halfway point of my interest in BioCryst more than 5 years ago, I kept and keep paying more in the short-term. I imagine some folks expect the company to sell itself lock stock and barrel to Roche or one of the big pharmas.
We follow the company because its PNP inhibitor for cancers shows promise. I sold not one share when the stock ran to $14 or wherever it was more than a year ago. I am vaccinated on this entirely. For those who might believe I am pumping and dumping, I can say no way. Six or so years ago I settled stock-trading charges in a USA civil case that changed my life. It will never happen again … and our subscribers at Stockhouse and at Ticker Trax, I believe, realize that.
Endeavour Silver (TSX: T.EDR, Stock Forum) and (AMEX: EXK, Stock Forum) runs two silver-gold mines in Mexico. Silver output is now 826,000 ounces a quarter. GOLD output rose to 4,460 ounces. BIG rises. Cash costs fell 15 per cent. Gold is the story for this Mexico silver miner, soon to be one of the top-15 in the world. Bravo to the team up there in Vancouver, Canada. It is all here at Stockhouse.
NEW ORLEANS: This autumn I will be making two or three appearances outside of prospect tours. One of them is in New Orleans, where I appear each year at Brien Lundin’s New Orleans Investment Conference.
If you’d like to join our Stockhouse and Ticker Trax audience at the late-October show, please register and pay up at this link: REGISTER FOR NEW ORLEANS. You get a discount on the price at that address. And I have something special planned for New Orleans. It’s my favorite investment show – along with the longstanding San Francisco conference in November.
STUFF: Our Ticker Trax landing page has more stuff, videos included. Please see: https://stockhouse.com/TickerTrax/Default.aspx.
- In Sweden: producer Gold Ore Resources Ltd. (TSX: T.GOZ, Stock Forum) is of interest. Gold Ore is about to record its one-millionth ounce of gold production. The mine is called Bjorkdal Gold Mine. I now own a small number of shares – bought at 56 cents each Canadian. The company’s latest numbers are out and look promising. Please see Shock Rock article on Stockhouse. I hope to visit the property in early September.
- ON TAP:Properties I have visited or are on tap for further investor exploration for Ticker Trax include Timberline Resources Ltd. (TSX: V.TBR, Stock Forum) and (AMEX: TLR, Stock Forum) in Montana. Butte Highlands is the name of the fast-developing mine. We own no Timberline. (Also: Neither of these two companies pay Stockhouse or Ticker Trax in exchange for coverage, research or preference as a Planetary Prospect or a subject of any article.)
- STUFF: Our Ticker Trax landing page has more stuff, videos included. Please see: https://stockhouse.com/TickerTrax/Default.aspx.
NEW ORLEANS: This autumn I will be making two or three appearances outside of prospect tours. One of them is in New Orleans, where I appear each year at Brien Lundin’s New Orleans Investment Conference.
If you’d like to join our Stockhouse and Ticker Trax audience at the late-October show, please register and pay up at this link: REGISTER FOR NEW ORLEANS. You get a large discount on the price at that address. And I have something special planned for New Orleans. It’s my favorite investment show – along with the longstanding San Francisco conference in November.
Ticker Trax™ is in place because its fiscal loyalty is to subscribers who are looking for radically cheap investments. Our service, started in November 2008, researches a select group of Planetary Prospects™ with legitimate shots at rising significantly in the span of two years, maybe less and maybe more. We hope you out there in the Stockhouse audience consider joining our expanding service, now in its 21th month. It is at www.tickertrax.com. Needy wanna-be subscribers can petition Stockhouse with a plea and a suggested price for the $399 service at members@stockhouse.com. The service is thriving amid a gloomy summer for natural resources stocks.
Ticker Trax™
Please see Stockhouse for a selection of our Ticker Trax research and our password-protected library for subscribers. Please see our Ticker Traxpassword-protected library for coverage of drug discovery and of gold, uranium, copper, silver, moly and platinum.
(All photos by Thom Calandra. Thom and his family own shares of each of the 12 Planetary Prospects. Thom’s personal holdings are available for all to see on Stockhouse, the Canada publishing company. Subscribers are informed well in advance of any shift in research regarding Planetary Prospects and any purchase or sales decisions.)
Ticker Trax™Please see tickertrax.com to learn more about this wealth service and its Planetary Prospects. For an index of free Thom Calandra articles, please click here. For an entire explanation of our strategies, research methods and disclosure procedures regarding all aspects of Ticker Trax and our Stockhouse reports, please visit our readily available Stockhouse articles. Please see this one in particular: Core Box Revealed. Thom Calandra’s on-site tours of properties are paid in part by the hosting companies and in part by Stockhouse and Thom Calandra. For the password-protected Ticker Traxlibrary, please see: www.tickertrax.com/Login.aspx.
HOLDINGS: Thom’s holdings are listed for Stockhouse members at www.Stockhouse.com under the “portfolio setting” for user TCALANDRA. It is public and free to view. He and his family own recently minted gold and silver coins and shares of about 30 public and two private companies.
THOM CALANDRA of Ticker Trax helps his audience find value in a quagmire of investment choices. Thom co-founded CBS MarketWatch and MarketWatch.com. As the voice of Thom Calandra's StockWatch and The Calandra Report, Thom pegged $300-ounce gold as a long-term hold in 1999 and in 2000. He has been covering life-sciences and natural resources since 1988.
Thom Calandra and Stockhouse produce this and other free reports. Please visit www.Stockhouse.com.